TSE:AUP - Aurinia Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$28.00
  • Forecasted Upside: 62.22 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$17.26
▲ +0.7 (4.23%)

This chart shows the closing price for AUP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aurinia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUP

Analyst Price Target is C$28.00
▲ +62.22% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is C$28.00, with a high forecast of C$28.00 and a low forecast of C$28.00. The average price target represents a 62.22% upside from the last price of C$17.26.

This chart shows the closing price for AUP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Aurinia Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/21/2021Royal Bank of CanadaReiterated RatingOutperformC$28.00
5/7/2021Bloom BurtonUpgradeAccumulate ➝ Buy
5/7/2021Royal Bank of CanadaLower Price TargetOutperformC$28.00
4/29/2021Royal Bank of CanadaReiterated RatingOutperformC$32.00
11/3/2020Bloom BurtonDowngradeBuy ➝ Accumulate
10/17/2019Cantor FitzgeraldReiterated RatingOverweight
10/2/2019Bloom BurtonReiterated RatingBuy
3/20/2019Cantor FitzgeraldReiterated RatingOverweight
3/19/2019SVB LeerinkReiterated RatingOutperform
10/6/2017Seaport Global SecuritiesReiterated RatingBuy
5/15/2017SVB LeerinkReiterated RatingOutperform
11/4/2016Bloom BurtonReiterated RatingBuy
11/1/2016MackieReiterated RatingSpeculative Buy
(Data available from 6/22/2016 forward)
Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Read More

Today's Range

Now: C$17.26
Low: C$16.58
High: C$17.33

50 Day Range

MA: C$15.46
Low: C$12.07
High: C$17.54

52 Week Range

Now: C$17.26
Low: C$11.77
High: C$26.00

Volume

290,400 shs

Average Volume

189,976 shs

Market Capitalization

C$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Aurinia Pharmaceuticals in the last twelve months: Bloom Burton, and Royal Bank of Canada.
View the latest analyst ratings for AUP.

What is the current price target for Aurinia Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Aurinia Pharmaceuticals in the last year. Their average twelve-month price target is C$28.00, suggesting a possible upside of 62.2%. Royal Bank of Canada has the highest price target set, predicting AUP will reach C$28.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of C$28.00 for Aurinia Pharmaceuticals in the next year.
View the latest price targets for AUP.

What is the current consensus analyst rating for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AUP will outperform the market and that investors should add to their positions of Aurinia Pharmaceuticals.
View the latest ratings for AUP.

What other companies compete with Aurinia Pharmaceuticals?

How do I contact Aurinia Pharmaceuticals' investor relations team?

Aurinia Pharmaceuticals' physical mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company's listed phone number is +1-250-7084272. The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.